All About TALVEY (talquetamab) -a GPRC5D Bispecific Antibody for Myeloma

TALVEY™ (talquetamab-tgvs) is an innovative treatment for relapsed or refractory multiple myeloma. It's the first FDA-approved bispecific antibody that targets GPRC5D, a protein highly expressed on myeloma cells but limited on normal tissues. TALVEY works by bringing a patient’s T cells (part of the immune system) into close contact with myeloma cells, helping the immune system directly attack and destroy them.

Approved for use after at least four prior lines of therapy—including a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody—TALVEY offers a new option for patients who have exhausted standard treatments. It’s given as a subcutaneous injection, with step-up dosing to help reduce the risk of cytokine release syndrome (CRS), a common side effect of T-cell engaging therapies.

This HealthTree University video will walk you through how TALVEY works, who it's for, how it's given, and what side effects patients should be aware of. Learn more about how this GPRC5D-targeted therapy is changing the landscape for myeloma patients. #Myeloma #TALVEY #MultipleMyelomaTreatment #Talquetamab #Immunotherapy #BispecificAntibody


Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_so...

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.